Form 8-K

8-K — APTARGROUP, INC.

Accession: 0000896622-26-000165

Filed: 2026-07-30

Period: 2026-07-30

CIK: 0000896622

SIC: 3089 (PLASTICS PRODUCTS, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — atr-20260730.htm (Primary)

EX-99.1 (atr-20260630x8kexx991.htm)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: atr-20260730.htm · Sequence: 1

atr-20260730

0000896622FALSE00008966222026-07-302026-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 30, 2026

Date of Report (Date of earliest event reported)

AptarGroup, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-11846 36-3853103

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014

(Address of principal executive offices)

Registrant’s telephone number, including area code: 815-477-0424.

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $.01 par value ATR New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2026, AptarGroup, Inc. announced certain information related to its results of operations for the quarter ended June 30, 2026. The press release regarding this announcement is furnished as Exhibit 99.1 hereto.

The information in Item 2.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release issued by AptarGroup, Inc. dated July 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AptarGroup, Inc.

Date: July 30, 2026

By: /s/ Vanessa Kanu

Vanessa Kanu

Executive Vice President and

Chief Financial Officer

EX-99.1

Filename: atr-20260630x8kexx991.htm · Sequence: 2

Document

Exhibit 99.1

Aptar Reports Second Quarter 2026 Results

Crystal Lake, Illinois, July 30, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following second quarter results for the period ended June 30, 2026, as compared to the corresponding period of the last fiscal year.

Second Quarter 2026 Highlights

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)

•Reported sales increased 6% to over $1 billion for the first time, and core sales increased 1%

•Reported net income was $88 million and reported earnings per share were $1.36

•Adjusted EBITDA margin was 20.7% compared to 22.6% in the prior year

•Adjusted earnings per share were $1.42

•Returned $81 million in the quarter and $212 million year-to-date to shareholders through share repurchases and dividends

“We were pleased to deliver revenue growth across all three segments during the quarter. Aptar Pharma continued to lead the way, driven by double-digit growth in consumer healthcare, and high single-digit growth in injectables and prescription, excluding emergency medicine. In Beauty, strong demand in prestige fragrance solutions supported growth, while Closures benefited from continued strength in beverage dispensing. While margins are currently impacted by product mix and operational factors, we remain confident in the company’s long-term margin structure, supported by strong demand trends across key Pharma franchises, continued momentum in Closures, and the actions underway to enhance operational performance. As I conclude my tenure as CEO at Aptar, I am pleased to hand the company over following a quarter that reflects solid performance, a strong balance sheet and an improving growth trajectory in the outlook. These results demonstrate the dedication of our teams, the strength of our innovation-led portfolio and our ability to create value for customers across attractive end markets,” said Stephan B. Tanda, Aptar President and CEO.

Second Quarter Results

For the quarter ended June 30, 2026, reported sales increased 6% to $1.03 billion compared to $966 million in the prior year and core sales increased 1% compared to the prior year period.

Second Quarter Segment Sales Analysis

(Change Over Prior Year)

Pharma Beauty Closures Total AptarGroup

Reported Sales Growth 4% 10% 7% 6%

Currency Effects (1)

(2)% (3)% (3)% (2)%

Acquisitions (1)% (6)% 0% (3)%

Core Sales Growth 1% 1% 4% 1%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Pharma’s reported sales increased 4% compared to the prior year period, with a currency contribution of 2%. Excluding acquisitions, core sales increased 1%. Adjusting for emergency medicine destocking, Pharma delivered high single-digit core sales growth in the quarter. Performance was supported by continued growth across a number of prescription, consumer healthcare and injectable applications, including central nervous system, asthma and COPD therapies, nasal decongestants, eye care solutions, and demand related to biologics, GLP-1 therapies and vaccines. These growth drivers were partially offset by the anticipated reduction in emergency medicine sales and slightly lower sales within active material science solutions. Adjusted EBITDA margin was 33.6%, a decrease of 180 basis points, reflecting a short-term unfavorable product mix, while royalties and productivity improvements continued to positively impact margins.

Beauty’s reported sales increased 10% when compared to the prior year period, driven by a 3% benefit from currency changes and a 6% contribution from acquisitions, with core sales growth of 1%. There was increased demand for prestige fragrance dispensing, color cosmetics, as well as hair care applications. Adjusted EBITDA margin was 12.2%, a decline of 190 basis points, primarily due to lower product volumes, unfavorable mix and the timing of resin pass throughs.

Closures’ reported sales rose 7% from the prior year quarter and core sales grew 4%, with a 3% currency benefit. Beverage sales grew significantly, led by strong demand for bottled water and continued momentum from our latest dispensing closure innovation. Food sales were up year over year, however, lower tooling sales drove a decline in core sales. Adjusted EBITDA margin was 14.9%, a decline of 200 basis points, primarily due to temporary headwinds as a result of the ramp up of new production lines and previously reported maintenance.

Reported second quarter earnings per share of $1.36 compared to $1.67 reported a year ago. Adjusted earnings per share were $1.42, compared to the prior year period’s adjusted earnings per share of $1.68, including comparable exchange rates. The second quarter reported effective tax rate was 23.5% and the adjusted effective tax rate was 23.7%, compared to the prior year period’s reported effective tax rate of 20.0% and adjusted effective tax rate of 20.0%.

Six Months Year-to-Date Results

For the six months ended June 30, 2026, reported sales increased 8% to $2.01 billion compared to $1.85 billion in the prior year and core sales increased 1%.

Six Months Year-To-Date Segment Sales Analysis

(Change Over Prior Year)

Pharma Beauty Closures Total AptarGroup

Total Reported Sales Growth 5% 14% 6% 8%

Currency Effects (1)

(4)% (6)% (4)% (4)%

Acquisitions (1)% (6)% 0% (3)%

Core Sales Growth 0% 2% 2% 1%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

For the six months ended June 30, 2026, Aptar’s reported earnings per share were $2.48, a decrease of 12%, compared to $2.83 reported a year ago. For the first six months of the year 2026, adjusted earnings per share were $2.61 and decreased 12% from prior year adjusted earnings per share of $2.98, including comparable exchange rates. The current year had a reported effective tax rate of 23.0% and an adjusted effective tax rate of 23.2% compared to the prior year reported and adjusted effective tax rates of 22.5% and 22.6%, respectively.

Outlook

Regarding Aptar’s outlook, Tanda stated, “In alignment with Gael Touya, who will assume the role of CEO on September 1, we enter the third quarter with confidence. We expect solid growth across all three segments. In Pharma, injectables and consumer healthcare should continue to perform well. Demand for prescription dispensing systems, excluding emergency medicine, remains strong, and as previously discussed we anticipate the headwind of emergency medicine destocking to abate by the fourth quarter. We believe Beauty will see growth in key areas, such as in the fragrance and facial skin care end market. In Closures, we anticipate demand to remain strong and operational performance continues to improve. Supported by our innovation pipeline and strong market positions, these trends support our outlook for the third quarter.”

Aptar currently expects adjusted earnings per share for the third quarter of 2026 to be in the range of $1.45 to $1.53. This guidance assumes an effective tax rate range of 22.5% to 24.5%. The earnings per share guidance range is assuming a 1.14 Euro to USD exchange rate.

Cash Dividends and Share Repurchases

As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026. During the second quarter, Aptar repurchased 403 thousand shares for $50 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

Open Conference Call

There will be a conference call held on Friday, July 31, 2026 at 8:00 a.m. Central Time to discuss the company’s second quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. For the three and six months ended June 30, 2026, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of the company's routine activities, such as restructuring, acquisition costs and other special items.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to keep pace with competition and technological advances, including in connection with the shifting of Pharma origination to less regulated markets; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, including rising interest rates; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

815-479-5530

Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(In Thousands, Except Per Share Data)

Consolidated Statements of Income

Three Months Ended

June 30,

Six Months Ended

June 30,

2026

2025

2026

2025

Net Sales $ 1,026,508 $ 966,009 $ 2,009,376 $ 1,853,314

Cost of Sales (exclusive of depreciation and amortization shown below) 660,991 598,994 1,291,950 1,149,885

Selling, Research & Development and Administrative 157,735 151,139 325,337 306,416

Depreciation and Amortization 79,641 69,904 155,366 135,551

Restructuring Initiatives 1,419 1,579 2,505 3,621

Operating Income 126,722 144,393 234,218 257,841

Other Income (Expense):

Interest Expense (16,001) (10,850) (32,943) (22,201)

Interest Income 2,787 1,880 6,429 4,694

Net Investment Gain (Loss) 937 2,102 (149) 1,006

Equity in Results of Affiliates 1,404 2,309 2,118 4,395

Miscellaneous Expense, net (802) (120) (855) (6)

Income before Income Taxes 115,047 139,714 208,818 245,729

Provision for Income Taxes 27,037 27,982 48,041 55,334

Net Income $ 88,010 $ 111,732 $ 160,777 $ 190,395

Net (Income) Loss Attributable to Noncontrolling Interests (152) (12) (156) 123

Net Income Attributable to Redeemable Noncontrolling Interests (285) — (374) —

Net Income Attributable to AptarGroup, Inc. $ 87,573 $ 111,720 $ 160,247 $ 190,518

Net Income Attributable to AptarGroup, Inc. per Common Share:

Basic $ 1.38 $ 1.69 $ 2.51 $ 2.88

Diluted $ 1.36 $ 1.67 $ 2.48 $ 2.83

Average Numbers of Shares Outstanding:

Basic 63,634 65,995 63,841 66,132

Diluted 64,208 67,048 64,504 67,262

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Balance Sheets

June 30, 2026 December 31, 2025

ASSETS

Cash and Equivalents $ 190,402 $ 402,424

Short-term Investments 6,864 7,109

Accounts and Notes Receivable, Net 897,660 803,830

Inventories 580,136 537,845

Prepaid and Other 159,754 142,354

Total Current Assets 1,834,816 1,893,562

Property, Plant and Equipment, Net 1,645,981 1,676,479

Goodwill 1,069,666 1,077,898

Other Assets 582,751 604,780

Total Assets $ 5,133,214 $ 5,252,719

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY

Short-Term Obligations $ 249,239 $ 343,531

Accounts Payable, Accrued and Other Liabilities 887,308 822,913

Total Current Liabilities 1,136,547 1,166,444

Long-Term Obligations 1,118,415 1,139,433

Deferred Liabilities and Other 203,807 234,617

Total Liabilities 2,458,769 2,540,494

Redeemable Noncontrolling Interests 27,722 26,244

Total Mezzanine Equity 27,722 26,244

AptarGroup, Inc. Stockholders' Equity 2,628,293 2,668,096

Noncontrolling Interests in Subsidiaries 18,430 17,885

Total Stockholders' Equity 2,646,723 2,685,981

Total Liabilities, Mezzanine Equity and Stockholders' Equity $ 5,133,214 $ 5,252,719

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Statement of Cash Flows

Six Months Ended June 30,

2026

2025

Cash Flows from Operating Activities:

Net income $ 160,777 $ 190,395

Adjustments to reconcile net income to net cash provided by operations:

Depreciation 132,792 113,720

Amortization 22,574 21,831

Stock-based compensation 24,072 27,208

Provision for CECL 491 769

Loss (gain) on disposition of fixed assets 776 (366)

Net loss (gain) on remeasurement of equity securities 149 (1,006)

Deferred income taxes (3,098) (21,322)

Defined benefit plan expense 6,885 6,720

Equity in results of affiliates (2,118) (4,395)

Impairment loss 1,550 —

Changes in balance sheet items, excluding effects from foreign currency adjustments:

Accounts and other receivables (99,336) (83,207)

Inventories (48,178) (15,951)

Prepaid and other current assets (18,940) (21,141)

Accounts payable, accrued and other liabilities 67,020 21,653

Income taxes payable (5,761) (908)

Retirement and deferred compensation plan liabilities 64 (10,579)

Retirement and deferred compensation plan assets (13,340) (7,537)

Other changes, net (4,199) (7,184)

Net Cash Provided by Operations 222,180 208,700

Cash Flows from Investing Activities:

Capital expenditures (122,959) (120,287)

Proceeds from government grants — 3,308

Proceeds from sale of property, plant and equipment 2,635 79

(Purchases) and maturities of short-term investments (108) 2,819

Acquisition of business, net of cash acquired and release of escrow (156) (7,934)

Acquisition of intangible assets, net (893) (4,006)

Notes receivable, net (406) (49)

Net Cash Used by Investing Activities (121,887) (126,070)

Cash Flows from Financing Activities:

Proceeds from notes payable and overdrafts 8,052 —

Repayments of notes payable and overdrafts (8,820) —

Proceeds and (repayments) of short term revolving credit facility, net 37,500 69,103

Proceeds from long-term obligations 6,063 885

Repayments of long-term obligations (155,942) (32,950)

Payment of contingent consideration obligation (3,730) —

Dividends paid (61,531) (59,641)

Proceeds from stock option exercises 18,981 10,561

Purchase of treasury stock (149,973) (150,000)

Redeemable noncontrolling interest 1,112 —

Net Cash Used by Financing Activities (308,288) (162,042)

Effect of Exchange Rate Changes on Cash (4,027) 17,296

Net Decrease in Cash and Equivalents and Restricted Cash (212,022) (62,116)

Cash and Equivalents and Restricted Cash at Beginning of Period 404,849 223,844

Cash and Equivalents and Restricted Cash at End of Period $ 192,827 $ 161,728

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Three Months Ended

June 30, 2026

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 1,026,508 $ 458,167 $ 367,454 $ 200,887 $ — $ —

Reported net income $ 88,010

Reported income taxes 27,037

Reported income before income taxes 115,047 110,596 18,575 15,235 (16,145) (13,214)

Adjustments:

Restructuring initiatives 1,419 (66) 1,417 87 (19)

Net investment gain (937) — — — (937)

Realized gain on investments included in net investment gain above 88 — — — 88

Transaction costs related to acquisitions 38 38 — — —

Other special items 4,077 4,077 — — —

Adjusted earnings before income taxes 119,732 114,645 19,992 15,322 (17,013) (13,214)

Interest expense 16,001 16,001

Interest income (2,787) (2,787)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 132,946 114,645 19,992 15,322 (17,013) —

Depreciation and amortization 79,641 39,260 24,750 14,527 1,104

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 212,587 $ 153,905 $ 44,742 $ 29,849 $ (15,909) $ —

Reported net income margins (Reported net income / Reported Net Sales) 8.6 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.7 % 33.6 % 12.2 % 14.9 %

Three Months Ended

June 30, 2025

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 966,009 $ 442,589 $ 334,849 $ 188,571 $ — $ —

Reported net income $ 111,732

Reported income taxes 27,982

Reported income before income taxes 139,714 122,594 24,628 17,546 (16,084) (8,970)

Adjustments:

Restructuring initiatives 1,579 68 626 890 (5)

Net investment gain (2,102) — — — (2,102)

Transaction costs related to acquisitions 344 — 344 — —

Adjusted earnings before income taxes 139,535 122,662 25,598 18,436 (18,191) (8,970)

Interest expense 10,850 10,850

Interest income (1,880) (1,880)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 148,505 122,662 25,598 18,436 (18,191) —

Depreciation and amortization 69,904 34,169 21,475 13,447 813

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 218,409 $ 156,831 $ 47,073 $ 31,883 $ (17,378) $ —

Reported net income margins (Reported net income / Reported Net Sales) 11.6 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 22.6 % 35.4 % 14.1 % 16.9 %

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Six Months Ended

June 30, 2026

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 2,009,376 $ 896,727 $ 731,089 $ 381,560 $ — $ —

Reported net income $ 160,777

Reported income taxes 48,041

Reported income before income taxes 208,818 217,254 33,033 24,419 (39,374) (26,514)

Adjustments:

Restructuring initiatives 2,505 (61) 2,718 336 (488)

Net investment loss 149 — — — 149

Realized gain on investments included in net investment loss above 88 — — — 88

Transaction costs related to acquisitions 83 83 — — —

Purchase accounting adjustments related to acquisitions and investments 145 145 — — —

Other special items 7,804 7,804 — — —

Adjusted earnings before income taxes 219,592 225,225 35,751 24,755 (39,625) (26,514)

Interest expense 32,943 32,943

Interest income (6,429) (6,429)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 246,106 225,225 35,751 24,755 (39,625) —

Depreciation and amortization 155,366 74,903 49,473 28,751 2,239

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 401,472 $ 300,128 $ 85,224 $ 53,506 $ (37,386) $ —

Reported net income margins (Reported net income / Reported Net Sales) 8.0 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.0 % 33.5 % 11.7 % 14.0 %

Six Months Ended

June 30, 2025

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 1,853,314 $ 852,056 $ 640,556 $ 360,702 $ — $ —

Reported net income $ 190,395

Reported income taxes 55,334

Reported income before income taxes 245,729 233,706 41,309 29,879 (41,658) (17,507)

Adjustments:

Restructuring initiatives 3,621 258 1,021 2,242 100

Net investment loss (1,006) — — — (1,006)

Transaction costs related to acquisitions 344 — 344 — —

Adjusted earnings before income taxes 248,688 233,964 42,674 32,121 (42,564) (17,507)

Interest expense 22,201 22,201

Interest income (4,694) (4,694)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 266,195 233,964 42,674 32,121 (42,564) —

Depreciation and amortization 135,551 65,317 41,537 27,022 1,675 —

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 401,746 $ 299,281 $ 84,211 $ 59,143 $ (40,889) $ —

Reported net income margins (Reported net income / Reported Net Sales) 10.3 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.7 % 35.1 % 13.1 % 16.4 %

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

Income before Income Taxes $ 115,047 $ 139,714 $ 208,818 $ 245,729

Adjustments:

Restructuring initiatives 1,419 1,579 2,505 3,621

Net investment (gain) loss (937) (2,102) 149 (1,006)

Realized gain on investments included in net investment (gain) loss above 88 — 88 —

Transaction costs related to acquisitions 38 344 83 344

Purchase accounting adjustments related to acquisitions and investments — — 145 —

Other special items 4,077 — 7,804 —

Foreign currency effects (1) 1,245 10,237

Adjusted Earnings before Income Taxes $ 119,732 $ 140,780 $ 219,592 $ 258,925

Provision for Income Taxes $ 27,037 $ 27,982 $ 48,041 $ 55,334

Adjustments:

Restructuring initiatives 404 421 683 927

Net investment (gain) loss (229) (515) 37 (246)

Realized gain on investments included in net investment (gain) loss above 22 — 22 —

Transaction costs related to acquisitions 9 86 20 86

Purchase accounting adjustments related to acquisitions and investments — — 49 —

Other special items 1,074 — 2,027 —

Foreign currency effects (1) 249 2,305

Adjusted Provision for Income Taxes $ 28,317 $ 28,223 $ 50,879 $ 58,406

Net (Income) Loss Attributable to Noncontrolling Interests $ (152) $ (12) $ (156) $ 123

Net Income Attributable to Redeemable Noncontrolling Interests $ (285) $ — $ (374) $ —

Net Income Attributable to AptarGroup, Inc. $ 87,573 $ 111,720 $ 160,247 $ 190,518

Adjustments:

Restructuring initiatives 1,015 1,158 1,822 2,694

Net investment (gain) loss (708) (1,587) 112 (760)

Realized gain on investments included in net investment (gain) loss above 66 — 66 —

Transaction costs related to acquisitions 29 258 63 258

Purchase accounting adjustments related to acquisitions and investments — — 96 —

Other special items 3,003 — 5,777 —

Foreign currency effects (1) 996 7,932

Adjusted Net Income Attributable to AptarGroup, Inc. $ 90,978 $ 112,545 $ 168,183 $ 200,642

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

Average Number of Diluted Shares Outstanding 64,208 67,048 64,504 67,262

Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.36 $ 1.67 $ 2.48 $ 2.83

Adjustments:

Restructuring initiatives 0.02 0.02 0.03 0.04

Net investment (gain) loss (0.01) (0.03) — (0.01)

Realized gain on investments included in net investment (gain) loss above — — — —

Transaction costs related to acquisitions — — — —

Purchase accounting adjustments related to acquisitions and investments — — — —

Other special items 0.05 — 0.10 —

Foreign currency effects (1) 0.02 0.12

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.42 $ 1.68 $ 2.61 $ 2.98

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

AptarGroup, Inc.

Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)

(In Thousands)

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

Net Cash Provided by Operations $ 103,486 $ 125,958 $ 222,180 $ 208,700

Capital Expenditures (57,563) (63,425) (122,959) (120,287)

Proceeds from Government Grants — 3,308 — 3,308

Free Cash Flow $ 45,923 $ 65,841 $ 99,221 $ 91,721

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ending

September 30,

Expected 2026

2025

Income before Income Taxes $ 154,127

Adjustments:

Restructuring initiatives 2,168

Net investment loss 161

Gain from remeasurement of equity method investment (26,518)

Transaction costs related to acquisitions 748

Purchase accounting adjustments related to acquisitions and investments 1,148

Other special items 4,400

Foreign currency effects (1) (1,076)

Adjusted Earnings before Income Taxes $ 135,158

Provision for Income Taxes $ 26,295

Adjustments:

Restructuring initiatives 561

Net investment loss 39

Gain from remeasurement of equity method investment —

Transaction costs related to acquisitions 182

Purchase accounting adjustments related to acquisitions and investments 172

Other special items 1,078

Foreign currency effects (1) (184)

Adjusted Provision for Income Taxes $ 28,143

Net Income Attributable to Noncontrolling Interests $ (47)

Net Loss Attributable to Redeemable Noncontrolling Interests $ 142

Net Income Attributable to AptarGroup, Inc. $ 127,927

Adjustments:

Restructuring initiatives 1,607

Net investment loss 122

Gain from remeasurement of equity method investment (26,518)

Transaction costs related to acquisitions 566

Purchase accounting adjustments related to acquisitions and investments 976

Other special items 3,322

Foreign currency effects (1) (892)

Adjusted Net Income Attributable to AptarGroup, Inc. $ 107,110

Three Months Ending

September 30,

Expected 2026

2025

Average Number of Diluted Shares Outstanding 66,630

Net Income Attributable to AptarGroup, Inc. Per Diluted Share (3) $ 1.92

Adjustments:

Restructuring initiatives 0.02

Net investment loss —

Gain from remeasurement of equity method investment (0.40)

Transaction costs related to acquisitions 0.01

Purchase accounting adjustments related to acquisitions and investments 0.02

Other special items 0.05

Foreign currency effects (1) (0.01)

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) $1.45 - $1.53 $ 1.61

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.

(2) AptarGroup’s expected adjusted earnings per share range for the third quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 22.5% to 24.5%. This tax rate range compares to our third quarter of 2025 effective tax rate of 17.1% on reported earnings per share and 20.8% on adjusted earnings per share.

GRAPHIC

Filename: image.jpg · Sequence: 6

Binary file (4819 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Jul. 30, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Jul. 30, 2026

Entity Registrant Name

AptarGroup, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-11846

Entity Tax Identification Number

36-3853103

Entity Address, Address Line One

265 Exchange Drive

Entity Address, Address Line Two

Suite 301

Entity Address, City or Town

Crystal Lake

Entity Address, State or Province

Entity Address, Postal Zip Code

60014

City Area Code

815

Local Phone Number

477-0424

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $.01 par value

Trading Symbol

ATR

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0000896622

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration